{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:04:34Z","timestamp":1790949874250,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41443-020-0263-3","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T08:33:29Z","timestamp":1585038809000},"page":"303-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u201cDoc, if it were you, what would you do?\u201d: a survey of Men\u2019s Health specialists\u2019 personal preferences regarding treatment modalities"],"prefix":"10.1038","volume":"33","author":[{"given":"Maxwell","family":"Towe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farouk","family":"El-Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Carrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-0510","authenticated-orcid":false,"given":"Sam","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavoc","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-7012","authenticated-orcid":false,"given":"Ege Can","family":"Serefoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pastuszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal A.","family":"Yafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"263_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/heapro\/dan019","volume":"23","author":"JA Smith","year":"2008","unstructured":"Smith JA, Robertson S. Men\u2019s health promotion: a new frontier in Australia and the UK? Health Promot Int. 2008;23:283\u20139.","journal-title":"Health Promot Int"},{"key":"263_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1210\/jc.2015-3843","volume":"101","author":"S Bhasin","year":"2016","unstructured":"Bhasin S. A perspective on the evolving landscape in male reproductive medicine. J Clin Endocrinol Metab. 2016;101:827\u201336.","journal-title":"J Clin Endocrinol Metab"},{"key":"263_CR3","volume-title":"Understanding men and health: masculinities, identity and well-being","author":"S Robertson","year":"2007","unstructured":"Robertson S. Understanding men and health: masculinities, identity and well-being. UK: McGraw-Hill Education; 2007."},{"key":"263_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1743-6109.2005.20371.x","volume":"2","author":"M Sotomayor","year":"2005","unstructured":"Sotomayor M. The burden of premature ejaculation: the patient\u2019s perspective. J Sex Med. 2005;2:110\u20134.","journal-title":"J Sex Med"},{"key":"263_CR5","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/j.1743-6109.2008.00883.x","volume":"5","author":"R Rosen","year":"2008","unstructured":"Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, et al. Impact of Peyronie\u2019s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5:1977\u201384.","journal-title":"J Sex Med"},{"key":"263_CR6","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/j.1743-6109.2009.01674.x","volume":"7","author":"G Schnetzler","year":"2010","unstructured":"Schnetzler G, Banks I, Kirby M, Zou KH, Symonds T. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. J Sex Med. 2010;7:1237\u201346.","journal-title":"J Sex Med"},{"key":"263_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/tau.2016.10.04","volume":"6","author":"J Chiang","year":"2017","unstructured":"Chiang J, Yafi FA, Dorsey PJ Jr, Hellstrom WJ. The dangers of sexual enhancement supplements and counterfeit drugs to \u201ctreat\u201d erectile dysfunction. Transl Androl Urol. 2017;6:12.","journal-title":"Transl Androl Urol"},{"key":"263_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s11934-011-0212-2","volume":"12","author":"EC Serefoglu","year":"2011","unstructured":"Serefoglu EC, Hellstrom WJ. Treatment of Peyronie\u2019s disease: 2012 update. Curr Urol Rep. 2011;12:444\u201352.","journal-title":"Curr Urol Rep."},{"key":"263_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.21037\/tau.2016.04.04","volume":"5","author":"J Anaissie","year":"2016","unstructured":"Anaissie J, Yafi FA. A review of surgical strategies for penile prosthesis implantation in patients with Peyronie\u2019s disease. Transl Androl Urol. 2016;5:342.","journal-title":"Transl Androl Urol"},{"key":"263_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","volume":"338","author":"I Goldstein","year":"1998","unstructured":"Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N. Engl J Med. 1998;338:1397\u2013404.","journal-title":"N. Engl J Med"},{"key":"263_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/sj.ijir.3900713","volume":"13","author":"H Porst","year":"2001","unstructured":"Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192.","journal-title":"Int J Impot Res"},{"key":"263_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","volume":"168","author":"GB Brock","year":"2002","unstructured":"Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332\u20136.","journal-title":"J Urol"},{"key":"263_CR13","first-page":"791","volume":"100","author":"KE Berkseth","year":"2016","unstructured":"Berkseth KE, Thirumalai A, Amory JK. Pharmacologic therapy in men\u2019s health: hypogonadism, erectile dysfunction, and benign prostatic hyperplasia. Med Clin. 2016;100:791\u2013805.","journal-title":"Med Clin."},{"key":"263_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11934-003-0027-x","volume":"4","author":"SH Francis","year":"2003","unstructured":"Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep. 2003;4:457\u201365.","journal-title":"Curr Urol Rep."},{"key":"263_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.juro.2015.12.049","volume":"195","author":"ND Kitrey","year":"2016","unstructured":"Kitrey ND, Gruenwald I, Appel B, Shechter A, Massarwa O, Vardi Y. Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, Sham Controlled Study. J Urol. 2016;195:1550\u20135.","journal-title":"J Urol"},{"key":"263_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41443-019-0117-z","volume":"31","author":"I Sokolakis","year":"2019","unstructured":"Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. Int J Impot Res. 2019;31:177\u201394.","journal-title":"Int J Impot Res"},{"key":"263_CR17","doi-asserted-by":"crossref","first-page":"175628721983836","DOI":"10.1177\/1756287219838364","volume":"11","author":"JD Campbell","year":"2019","unstructured":"Campbell JD, Trock BJ, Oppenheim AR, Anusionwu I, Gor RA, Burnett AL. Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction. Therapeutic Adv Urol. 2019;11:1756287219838364.","journal-title":"Therapeutic Adv Urol"},{"key":"263_CR18","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.jsxm.2019.07.016","volume":"16","author":"P Capogrosso","year":"2019","unstructured":"Capogrosso P, Frey A, Jensen CF, Rastrelli G, Russo GI, Torremade J, et al. Low-intensity shock wave therapy in sexual medicine\u2014clinical recommendations from the European Society of Sexual Medicine (ESSM). J Sex Med. 2019;16:1490\u2013505.","journal-title":"J Sex Med"},{"key":"263_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.sxmr.2016.02.003","volume":"4","author":"TC Peak","year":"2016","unstructured":"Peak TC, Anaissie J, Hellstrom WJ. Current perspectives on stem cell therapy for erectile dysfunction. Sex Med Rev. 2016;4:247\u201356.","journal-title":"Sex Med Rev."},{"key":"263_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.sxmr.2018.12.006","volume":"7","author":"S Scott","year":"2019","unstructured":"Scott S, Roberts M, Chung E. Platelet-rich plasma and treatment of erectile dysfunction: Critical review of literature and global trends in platelet-rich plasma clinics. Sex Med Rev. 2019;7:306\u201312.","journal-title":"Sex Med Rev"},{"key":"263_CR21","unstructured":"Sexual Medicine Society of North America. Position statement: ED restorative (regenerative) therapies; 2019. http:\/\/www.smsna.org\/V1\/news\/433-smsna-position-statement-on-restorative-therapies-for-ed."},{"key":"263_CR22","doi-asserted-by":"crossref","unstructured":"Shindel A, Nelson C, Brandes S. Urologist practice patterns in the management of premature ejaculation: a nationwide survey. J Sex Med. 2008;5:199\u2013205.","DOI":"10.1111\/j.1743-6109.2007.00638.x"},{"key":"263_CR23","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","volume":"14","author":"HM Nguyen","year":"2017","unstructured":"Nguyen HM, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJ. Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease. J Sex Med. 2017;14:1220\u20135.","journal-title":"J Sex Med"},{"key":"263_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","volume":"94","author":"KK Yang","year":"2016","unstructured":"Yang KK, Bennett N. Peyronie\u2019s disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology. 2016;94:143\u20137.","journal-title":"Urology."},{"key":"263_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","volume":"100","author":"J Anaissie","year":"2017","unstructured":"Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJ. Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie\u2019s disease. Urology. 2017;100:125\u201330.","journal-title":"Urology."},{"key":"263_CR26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1743-6109.2007.00674.x","volume":"5","author":"AW Shindel","year":"2008","unstructured":"Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie\u2019s disease: a nationwide survey. J Sex Med. 2008;5:954\u201364.","journal-title":"J Sex Med"},{"key":"263_CR27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie\u2019s disease: AUA guideline. J Urol. 2015;194:745\u201353.","journal-title":"J Urol"},{"key":"263_CR28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","volume":"13","author":"G Corona","year":"2014","unstructured":"Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327\u201351.","journal-title":"Expert Opin Drug Saf"},{"key":"263_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.21037\/tau.2016.08.17","volume":"5","author":"AW Pastuszak","year":"2016","unstructured":"Pastuszak AW, Rodriguez KM, Nguyen TM, Khera M. Testosterone therapy and prostate cancer. Transl Androl Urol. 2016;5:909.","journal-title":"Transl Androl Urol"},{"key":"263_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","volume":"200","author":"JP Mulhall","year":"2018","unstructured":"Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423\u201332.","journal-title":"J Urol"},{"key":"263_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0197-2456(02)00263-5","volume":"24","author":"OM Bautista","year":"2003","unstructured":"Bautista OM, Kusek JW, Nyberg LM Jr, McConnell JD, Bain RP, Miller G, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003;24:224\u201343.","journal-title":"Control Clin Trials"},{"key":"263_CR32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cct.2007.07.008","volume":"28","author":"P Siami","year":"2007","unstructured":"Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart\u00ae and Tamsulosin) trial rationale and study design. Contemp Clin Trials. 2007;28:770\u20139.","journal-title":"Contemp Clin Trials"},{"key":"263_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jsm.12333","volume":"11","author":"KT McVary","year":"2014","unstructured":"McVary KT, Gange SN, Shore ND, Bolton DM, Cowan BE, Brown BT, et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med. 2014;11:279\u201387.","journal-title":"J Sex Med"},{"key":"263_CR34","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the LIFT Study. J Urol. 2013;190:2161\u20137.","journal-title":"J Urol"},{"key":"263_CR35","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bju.13714","volume":"119","author":"C Gratzke","year":"2017","unstructured":"Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2\u2010year results of the BPH 6 prospective, multicentre, randomized study. BJU Int. 2017;119:767\u201375.","journal-title":"BJU Int."},{"key":"263_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-019-0903-7","volume":"20","author":"Z Green","year":"2019","unstructured":"Green Z, Westwood J, Somani BK. What\u2019s new in Rezum: a transurethral water vapour therapy for BPH. Curr Urol Rep. 2019;20:39.","journal-title":"Curr Urol Rep."},{"key":"263_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","volume":"126","author":"KT McVary","year":"2019","unstructured":"McVary KT, Rogers T, Roehrborn CG. Rez\u016bm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019;126:171\u20139.","journal-title":"Urology."},{"key":"263_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.urology.2018.12.002","volume":"125","author":"PJ Gilling","year":"2019","unstructured":"Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. Urology. 2019;125:169\u201373.","journal-title":"Urology."},{"key":"263_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41443-018-0045-3","volume":"30","author":"FA Yafi","year":"2018","unstructured":"Yafi FA, Tallman CT, Seard ML, Jordan ML. Aquablation outcomes for the US cohort of men with LUTS due to BPH in large prostates (80\u2013150 cc). Int J Impot Res. 2018;30:209.","journal-title":"Int J Impot Res"}],"updated-by":[{"DOI":"10.1038\/s41443-020-0266-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000}}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-020-0263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-020-0263-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-020-0263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T08:17:16Z","timestamp":1628669836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-020-0263-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["263"],"URL":"https:\/\/doi.org\/10.1038\/s41443-020-0263-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41443-020-0266-0","asserted-by":"object"}]},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"5 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41443-020-0266-0","URL":"https:\/\/doi.org\/10.1038\/s41443-020-0266-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FAY is a consultant for Coloplast. AP is an advisor and speaker for Endo Pharmaceuticals, and received research and fellowship support from this entity. He is also an advisor for Boston Scientific and an advisor for Antares Pharmaceuticals. He is a speaker for Bayer AG. He is the founder of and maintains a leadership role in Woven Health. RC is a consultant for Coloplast, a consultant for Boston Scientific, and a consultant for Endo Pharmaceuticals. All other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}